155 related articles for article (PubMed ID: 15165174)
1. Impact of proteomics on bladder cancer research.
Celis JE; Gromova I; Moreira JM; Cabezon T; Gromov P
Pharmacogenomics; 2004 Jun; 5(4):381-94. PubMed ID: 15165174
[TBL] [Abstract][Full Text] [Related]
2. Proteome-based diagnostics and prognosis of bladder transitional cell carcinoma.
Wu TF; Ku WL; Tsay YG
Expert Rev Proteomics; 2007 Oct; 4(5):639-47. PubMed ID: 17941819
[TBL] [Abstract][Full Text] [Related]
3. Genomics and proteomics tools for compound mode-of-action studies in drug discovery.
Kley N; Ivanov I; Meier-Ewert S
Pharmacogenomics; 2004 Jun; 5(4):395-404. PubMed ID: 15165175
[TBL] [Abstract][Full Text] [Related]
4. Proteomic analysis of tissue samples in translational breast cancer research.
Gromov P; Moreira JM; Gromova I
Expert Rev Proteomics; 2014 Jun; 11(3):285-302. PubMed ID: 24837673
[TBL] [Abstract][Full Text] [Related]
5. MHC-bound antigens and proteomics for novel target discovery.
Shoshan SH; Admon A
Pharmacogenomics; 2004 Oct; 5(7):845-59. PubMed ID: 15469407
[TBL] [Abstract][Full Text] [Related]
6. Mass spectrometry-based clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery.
Matta A; Ralhan R; DeSouza LV; Siu KW
Mass Spectrom Rev; 2010; 29(6):945-61. PubMed ID: 20945361
[TBL] [Abstract][Full Text] [Related]
7. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways.
Wallerand H; Reiter RR; Ravaud A
Curr Opin Urol; 2008 Sep; 18(5):524-32. PubMed ID: 18670279
[TBL] [Abstract][Full Text] [Related]
8. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
9. Oncoproteomics: current trends and future perspectives.
Cho WC; Cheng CH
Expert Rev Proteomics; 2007 Jun; 4(3):401-10. PubMed ID: 17552924
[TBL] [Abstract][Full Text] [Related]
10. Genomics and proteomics: emerging technologies in clinical cancer research.
Chung CH; Levy S; Chaurand P; Carbone DP
Crit Rev Oncol Hematol; 2007 Jan; 61(1):1-25. PubMed ID: 17015021
[TBL] [Abstract][Full Text] [Related]
11. Translational studies for target-based drugs.
Nishio K; Arao T; Shimoyama T; Fujiwara Y; Tamura T; Saijo N
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():90-3. PubMed ID: 16273363
[TBL] [Abstract][Full Text] [Related]
12. Application of proteomic technologies to tumor analysis.
Misek DE; Imafuku Y; Hanash SM
Pharmacogenomics; 2004 Dec; 5(8):1129-37. PubMed ID: 15584879
[TBL] [Abstract][Full Text] [Related]
13. Clinical applications for targeted therapy in bladder cancer.
Adam L; Kassouf W; Dinney CP
Urol Clin North Am; 2005 May; 32(2):239-46, vii. PubMed ID: 15862621
[TBL] [Abstract][Full Text] [Related]
14. The Fourth International Peptide Symposium: discovery to drugs: the peptide pipeline.
Benson H; Toth I
Biopolymers; 2008; 90(5):588. PubMed ID: 18821571
[No Abstract] [Full Text] [Related]
15. Bladder cancer: translating molecular genetic insights into clinical practice.
Cheng L; Zhang S; MacLennan GT; Williamson SR; Lopez-Beltran A; Montironi R
Hum Pathol; 2011 Apr; 42(4):455-81. PubMed ID: 21106220
[TBL] [Abstract][Full Text] [Related]
16. Clinical proteomics and breast cancer: strategies for diagnostic and therapeutic biomarker discovery.
Bertucci F; Goncalves A
Future Oncol; 2008 Apr; 4(2):271-87. PubMed ID: 18407739
[TBL] [Abstract][Full Text] [Related]
17. Molecular therapeutic targets for bladder cancer.
Zacharakis E; Monem M; Joseph JV; Patel HR
Expert Rev Anticancer Ther; 2007 Dec; 7(12):1691-3. PubMed ID: 18062742
[No Abstract] [Full Text] [Related]
18. The molecular make-up of a tumour: proteomics in cancer research.
Kolch W; Mischak H; Pitt AR
Clin Sci (Lond); 2005 May; 108(5):369-83. PubMed ID: 15831087
[TBL] [Abstract][Full Text] [Related]
19. Use of proteomics for the identification of novel drug targets in brain diseases.
Morón JA; Devi LA
J Neurochem; 2007 Jul; 102(2):306-15. PubMed ID: 17419802
[TBL] [Abstract][Full Text] [Related]
20. Molecular alterations associated with bladder cancer initiation and progression.
Cordon-Cardo C
Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
